How to buy G1 Therapeutics (GTHX) stock

G1 Therapeutics, Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 122 staff and has a trailing 12-month revenue of around 0.00.

G1 Therapeutics stock price (NASDAQ: GTHX)

Use our graph to track the performance of GTHX stocks over time.

G1 Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$21.72
52-week range	$10.81 - $37.07
50-day moving average	$21.09
200-day moving average	$22.42
Wall St. target price	$59.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.70

Buy G1 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy G1 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of G1 Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

G1 Therapeutics price performance over time

Historical closes compared with the close of $21.72 from 2021-05-28

1 week (2021-07-14)	N/A
1 month (2021-06-25)	-9.42%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

G1 Therapeutics financials

Revenue TTM	$59.5 million
Gross profit TTM	$45.3 million
Return on assets TTM	-19.95%
Return on equity TTM	-39.87%
Profit margin	-159.11%
Book value	$5.84
Market capitalisation	$758.6 million

TTM: trailing 12 months

Shorting G1 Therapeutics shares

There are currently 5.8 million G1 Therapeutics shares held short by investors – that's known as G1 Therapeutics's "short interest". This figure is 2.7% down from 6.0 million last month.

There are a few different ways that this level of interest in shorting G1 Therapeutics shares can be evaluated.

G1 Therapeutics's "short interest ratio" (SIR)

G1 Therapeutics's "short interest ratio" (SIR) is the quantity of G1 Therapeutics shares currently shorted divided by the average quantity of G1 Therapeutics shares traded daily (recently around 1.1 million). G1 Therapeutics's SIR currently stands at 5.09. In other words for every 100,000 G1 Therapeutics shares traded daily on the market, roughly 5090 shares are currently held short.

However G1 Therapeutics's short interest can also be evaluated against the total number of G1 Therapeutics shares, or, against the total number of tradable G1 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case G1 Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 G1 Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1659% of the tradable shares (for every 100,000 tradable G1 Therapeutics shares, roughly 166 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against G1 Therapeutics.

Find out more about how you can short G1 Therapeutics stock.

G1 Therapeutics share dividends

We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.

G1 Therapeutics share price volatility

Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $10.81 up to $37.069. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.2261. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

G1 Therapeutics overview

G1 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc.

Frequently asked questions

What percentage of G1 Therapeutics is owned by insiders or institutions?
Currently 8.988% of G1 Therapeutics shares are held by insiders and 68.68% by institutions. How many people work for G1 Therapeutics?
Latest data suggests 122 work at G1 Therapeutics. When does the fiscal year end for G1 Therapeutics?
G1 Therapeutics's fiscal year ends in December. Where is G1 Therapeutics based?
G1 Therapeutics's address is: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709 What is G1 Therapeutics's ISIN number?
G1 Therapeutics's international securities identification number is: US3621LQ1099 What is G1 Therapeutics's CUSIP number?
G1 Therapeutics's Committee on Uniform Securities Identification Procedures number is: 3621LQ109